Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Nurix's NX-1607 Achieves Dose-Dependent Immune Activation, Tumor Biomarker Reductions, And Durable Clinical Benefit Across Multiple Advanced Solid Tumors

Author: Benzinga Newsdesk | October 20, 2025 03:23am

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies
NX-1607 demonstrated evidence of monotherapy anti-tumor activity with reductions in tumor biomarkers, tumor shrinkage, long-term stable disease, and a confirmed partial response in heavily pretreated patients
Data support initiation of expansion cohorts at the two highest doses tested as monotherapy or combination for the treatment of advanced solid tumors

Posted In: NRIX